Michelle Glidden
Nurse Practitioner · Hamden, CTNPI 1790899680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Merck$1K
- Novo Nordisk$628
- Pfizer$616
- Alnylam Pharmaceuticals Inc.$357
- Boehringer Ingelheim$322
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,01599%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 101 | $1,433 |
| Merck | 51 | $1,109 |
| Novo Nordisk | 30 | $628 |
| Pfizer | 41 | $616 |
| Alnylam Pharmaceuticals Inc. | 10 | $357 |
| Boehringer Ingelheim | 14 | $322 |
| Johnson & Johnson | 13 | $255 |
| Bayer | 8 | $246 |
| AstraZeneca | 14 | $221 |
| Bardy Diagnostics, Inc. | 13 | $178 |
| Irhythm Technologies, Inc. | 2 | $169 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $157 |
| Novartis | 7 | $142 |
| Esperion Therapeutics, Inc. | 5 | $129 |
| Amgen | 6 | $115 |
| Abbott | 2 | $90 |
| Medtronic | 3 | $86 |
| Cvrx, Inc. | 3 | $84 |
| Heartflow, Inc. | 4 | $82 |
| Actelion Pharmaceuticals US, Inc. | 3 | $80 |
| Impulse Dynamics (USA) Inc. | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $61 |
| Baxter Healthcare | 1 | $55 |
| Lilly USA, LLC | 2 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $52 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Watermark Medical, Inc. | 2 | $42 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Philips North America LLC | 1 | $24 |
| Angiodynamics, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $20 |
| Biotronik Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,111 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 130 | $160,098 |
| EliquisApixaban | 88 | $126,978 |
| XareltoRivaroxaban | 69 | $85,717 |
| FarxigaDapagliflozin Propanediol | 36 | $32,108 |
| Repatha SyringeEvolocumab | 26 | $18,288 |
| BrilintaTicagrelor | 13 | $15,825 |
| Repatha SureclickEvolocumab | 21 | $13,976 |
| EdarbiAzilsartan Medoxomil | 15 | $10,416 |
| Nebivolol Hcl | 83 | $5,348 |
| Metoprolol Succinate | 315 | $3,381 |
| Ranolazine ErRanolazine | 32 | $3,316 |
| Rosuvastatin Calcium | 266 | $2,491 |
| Olmesartan Medoxomil | 250 | $2,288 |
| Carvedilol | 262 | $1,695 |
| Atorvastatin Calcium | 194 | $1,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $142 | $160,098130 claims |
| PfizerEliquis | $616 | $126,97888 claims |
| Johnson & JohnsonXarelto | $255 | $85,71769 claims |
| AstraZenecaFarxiga, Brilinta | $221 | $47,93349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in Hamden
- Suni JacobHamden$15K
- Lindita VincaCheshire$427K
- Catherine MilnePlymouth$361K
- Michele NovellaDanbury$331K
- Tiffany RydzNewtown$49K
- Paul FidrychNorwich$23K
- Priscilla QuilterNorwich$21K
- Kimberly BoldonMiddletown$19K
- Emma RobinsonStamford$17K
- Janice TavaresBridgeport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.